Prognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer

Oncology Reports

Volumn 27, Issue 1, 2012, Pages 28-38

  Bernardi, M A ^a   Logullo, A F ^b   Pasini, F S ^c   Nonogaki, S ^d   Blumke, C ^e   Soares, F A ^a   Brentani, M M ^a,c  

^a A C CAMARGO CANCER CENTER   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d INSTITUTO ADOLFO LUTZ   (Brazil)

^e UNIVERSIDADE NOVE DE JULHO   (Brazil)

Author keywords

Breast cancer subgroups; Cancer stem cell; CD24; CD44; Claudin 7; Prognosis

Indexed keywords

BIOLOGICAL MARKER; CD24 ANTIGEN; CLAUDIN 7; CYTOKERATIN 18; CYTOKERATIN 5; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HERMES ANTIGEN; KI 67 ANTIGEN; PHENOBARBITAL; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; EVENT FREE SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; OVERALL SURVIVAL; PAGET NIPPLE DISEASE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD24; ANTIGENS, CD44; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CLAUDINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASTIC STEM CELLS; PROGNOSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84855263756     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1477     Document Type: Article

References (34)

1. Weigelt B, Geyer FC, Horlings HM, Kreike B, Halfwerk H and Reis-Filho JS: Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type. Mod Pathol 22: 1401-1414, 2009.
2. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000.
3. Carey LA, Perou CM, Livasy CA, et al: Race, breast cancer subtypes and survival in the Carolina Breast Cancer Study. JAMA 295: 2492-2502, 2006. (Pubitemid 43854964)
4. Weigelt B, Baehner FL and Reis-Filho JS: The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol 220: 263-280, 2010.
5. Cheang MC, Chia SK, Voduc D, et al: Ki-67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101: 736-750, 2009.
6. Prat A, Parker JS, Karginova O, et al: Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12: R68, 2010.
7. Dontu G, Al-Hajj M, Abdallah WM, Clarke MF and Wicha MS: Stem cells in normal breast development and breast cancer. Cell Prolif 1: 59-72, 2003. (Pubitemid 37521844)
8. Smalley M and Ashworth A: Stem cells and breast cancer: a field in transit. Nat Cancer 3: 832-844, 2003. (Pubitemid 37376981)
9. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988, 2003. (Pubitemid 36418143)
10. Shipitsin M, Campbell LL, Argani P, et al: Molecular definition of breast tumor heterogeneity. Cancer Cell 11: 259-273, 2007. (Pubitemid 46349843)
11. - phenotype is enriched in basal-like breast tumors. Breast Cancer Res 10: R53, 2008.
12. Park SY, Lee HE, Li H, Shipitsin M, Gelman R and Polyak K: Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res 16: 876-887, 2010.
13. - phenotype relates to 'triple-negative' state and unfavorable prognosis in breast cancer patients. Med Oncol 28: 745-752, 2011.
14. - breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 8: R59, 2006.
15. + tumor cells in invasive breast carcinomas. Hum Pathol 39: 1096-1102, 2008.
16. low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 11: 1154-1159, 2005.
17. Allred DC, Harvey JM, Berardo M, et al: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155-168, 1998. (Pubitemid 28144151)
18. Yang XR, Sherman ME, Rimm DL, et al: Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 16: 439-443, 2007. (Pubitemid 46548646)
19. Prat A and Perou CM: Deconstructing the molecular portraits of breast cancer. Mol Oncol 5: 5-23, 2011.
20. Pal SK, Childs BH and Pegram M: Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 125: 627-636, 2011.
21. Hill RP: Identifying cancer stem cells in solid tumors: case not proven. Cancer Res 66: 1891-1895, 2006.
22. Kim HJ, Kim MJ, Ahn SH, et al: Different prognostic significance of CD24 and CD44 expression in breast cancer according to hormone receptor status. Breast 20: 78-85, 2011.
23. Hwang-Verslues WW, Kuo WH, Chang PH, et al: Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PLoS One 4: e8377, 2009.
24. Klingbeil P, Natrajan R, Everitt G, et al: CD44 is overexpressed in basal-like breast cancers but is not a driver of 11p13 amplification. Breast Cancer Res Treat 120: 95-109, 2010.
25. Meyer MJ, Fleming JM, Ali MA, Pesesky MW, Ginsburg E and Vonderhaar BK: Dynamic regulation of CD24 and the invasive, CD44posCD24neg phenotype in breast cancer cell lines. Breast Cancer Res 11: R82, 2009.
26. Pandit TS, Kennette W, Mackenzie L, et al: Lymphatic metastasis of breast cancer cells is associated with differential gene expresion profiles that predict cancer stem cell-like properties and the ability to survive, establish and grow in a foreign environment. Int J Oncol 35: 297-308, 2009.
27. Diaz LK, Zhou X, Wright, et al: CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. Clin Cancer Res 11: 3309-3314, 2005. (Pubitemid 40627880)
28. Kristiansen G, Winzer KJ, Mayordomo E, et al: CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res 9: 4906-4913, 2003. (Pubitemid 37323297)
29. Lim SC and Oh SH: The role of CD24 in various human epithelial neoplasias. Pathol Res Pract 201: 479-486, 2005.
30. Baumann P, Cremers N, Kroese F, et al: CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res 65: 10783-10793, 2005. (Pubitemid 41715227)
31. Kim HJ, Kim JB, Lee, et al: Isolation of CD24(high) and CD24(low/-) cells from MCF-7: CD24 expression is positively related with proliferation, adhesion and invasion in MCF-7. Cancer Lett 258: 98-108, 2007. (Pubitemid 47600499)
32. Szasz AM, Tokes AM, Micsinai, et al: Prognostic significance of claudin expression changes in breast cancer with regional lymph node metastasis. Clin Exp Metastasis 28: 55-63, 2011.
33. Lanigan F, McKiernan E, Brennan DJ, et al: Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer. Int J Cancer 124: 2088-2097, 2009.
34. Myal Y, Leygue E and Blanchard AA: Claudin 1 in breast tumorigenesis: revelation of a possible novel 'claudin high' subset of breast cancers. J Biomed Biotechnol 2010: 956897, 2010.